For One Graduate, a Career in Pharmaceutical Leadership
Training the next generation of physician-scientists for healthcare and biomedical research careers is an integral component of the Department of Medicine's mission. Providing residents with direct access to cutting-edge medical research is part of the Internal Medicine Residency Program's proven track record of placing graduates in prestigious fellowships and onto future roles as the nation's academic medical leaders.
Wenru Song, MD, PhD
Wenru Song, MD, PhD, a graduate of the Internal Medicine Residency Program, is currently a medical director and clinical lead at Pfizer Oncology, as well as an adjunct faculty at Baylor Institute for Immunology Research (BIIR). Since joining Pfizer Oncology to lead a number of biologic compounds in the cancer immunotherapeutics and antibody-drug conjugate programs, he has gained broad experience and deep expertise in translational and clinical research in oncology drug development in a variety of hematological and solid tumor types.
"Montefiore has a special place in my heart and in my career development path," said Dr. Song. "I will be forever grateful for the opportunity to be trained and affiliated there, and for its wonderful educators like James Scheuer and other trainee colleagues and friends."
Dr. Song’s clinical interest is in medical oncology, especially lymphoma, and his own laboratory research had been focused on the development of effective cancer immunotherapy. He was among the first to show that genetically modified dendritic cells (DCs) expressing tumor antigens could serve as effective therapeutic cancer vaccines. He further demonstrated for the first time that intratumoral DC vaccination following conventional cancer therapy could serve as more effective and practical cancer immunotherapy, which has since been confirmed by other investigators. With the approval of three investigational new drug applications from the FDA, he started to translate his laboratory research findings by initiating phase I/II human clinical trials in patients with colon or pancreatic cancer at Stanford University and in patients with lymphoma at Baylor Sammons Cancer Center in Dallas.
Prior to joining Pfizer, Dr. Song was an associate investigator at BIIR and an attending oncologist physician at Texas Oncology/Baylor Sammons Cancer Center in Dallas. He studied medicine in China before coming to the United States for his PhD study in immunology. He completed a postdoctoral fellowship in cancer gene/immune therapy with Dr. Ronald Crystal at Cornell University Medical Center, a medical residency at Montefiore Medical Center/Albert Einstein College of Medicine, and a clinical oncology fellowship and research in cancer immunotherapy at Stanford University with Drs. Ronald Levy and Edgar Engleman.
Dr. Song has actively participated in community service and professional and scientific organizations, including the Chinese American Hematologist and Oncologist Network, the American Society of Hematology, the Chinese Society of Clinical Oncology, the International Society for Biological Therapy of Cancer (iSBTC), the American Society of Clinical Oncology, and most recently the NCI's Immune Response Modifier Pathway Prioritization Working Group and the iSBTCFDA-NCI Taskforce on Immunotherapy Biomarkers. He is board certified in medical oncology and internal medicine by the American Board of Internal Medicine.